Cargando…

Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report

Treatment of Stenotrophonomas maltophilia infections is difficult due to its predilection to form biofilms and susceptibility to a limited number of antibiotics. We report a case of S. maltophilia-associated periprosthetic joint infection successfully treated with a combination of the novel therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chambers, MaKenzie M., Gutowski, Christina J., Doktor, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204043/
https://www.ncbi.nlm.nih.gov/pubmed/37229181
http://dx.doi.org/10.1177/20499361231174292
_version_ 1785045758030905344
author Chambers, MaKenzie M.
Gutowski, Christina J.
Doktor, Katherine
author_facet Chambers, MaKenzie M.
Gutowski, Christina J.
Doktor, Katherine
author_sort Chambers, MaKenzie M.
collection PubMed
description Treatment of Stenotrophonomas maltophilia infections is difficult due to its predilection to form biofilms and susceptibility to a limited number of antibiotics. We report a case of S. maltophilia-associated periprosthetic joint infection successfully treated with a combination of the novel therapeutic agent, cefiderocol, and trimethoprim-sulfamethoxazole after debridement and implant retention.
format Online
Article
Text
id pubmed-10204043
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102040432023-05-24 Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report Chambers, MaKenzie M. Gutowski, Christina J. Doktor, Katherine Ther Adv Infect Dis Case Report Treatment of Stenotrophonomas maltophilia infections is difficult due to its predilection to form biofilms and susceptibility to a limited number of antibiotics. We report a case of S. maltophilia-associated periprosthetic joint infection successfully treated with a combination of the novel therapeutic agent, cefiderocol, and trimethoprim-sulfamethoxazole after debridement and implant retention. SAGE Publications 2023-05-21 /pmc/articles/PMC10204043/ /pubmed/37229181 http://dx.doi.org/10.1177/20499361231174292 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Chambers, MaKenzie M.
Gutowski, Christina J.
Doktor, Katherine
Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title_full Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title_fullStr Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title_full_unstemmed Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title_short Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report
title_sort cefiderocol for stenotrophomonas maltophilia prosthetic joint infection: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204043/
https://www.ncbi.nlm.nih.gov/pubmed/37229181
http://dx.doi.org/10.1177/20499361231174292
work_keys_str_mv AT chambersmakenziem cefiderocolforstenotrophomonasmaltophiliaprostheticjointinfectionacasereport
AT gutowskichristinaj cefiderocolforstenotrophomonasmaltophiliaprostheticjointinfectionacasereport
AT doktorkatherine cefiderocolforstenotrophomonasmaltophiliaprostheticjointinfectionacasereport